ClinicalTrials.gg
Not yet recruitingNCT07948109Updated Nov 19, 2026

YSCH-01 for Recurrent or Progressive Glioblastoma

A Phase 1 interventional study of YSCH-01 in Recurrent Glioblastoma (WHO-Grade IV Glioma), Progressive Glioblastoma and Recurrent Glioblastoma, sponsored by Shanghai Yuansong Biotechnology Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Shanghai Yuansong Biotechnology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

Updated Nov 19, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 143 studies in Glioblastoma with a site in China — 74 open to participants now, 81 under way, 7 of them phase 3. Glioblastoma · China.

Planned enrollment
68th of 128
32 · median 36
Started
2026
with 20 others
Phase 1
46 of 143
23 open now
Primary completion
2028-12
later than 65 of 80 live
Registered
143rd of 143
by date

Among the 143 studies in Glioblastoma with a site in China, this one is the 68th largest by planned enrollment of the 128 interventional ones that give a count, is one of 21 that started in 2026, is one of 46 in phase 1, reaches primary completion later than 65 of the 80 other live ones, and was the 143rd registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

74 of the 143 studies in Glioblastoma with a site in China are open now. Recruiting first, the newest first:

69 more — sign in →

All 74 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 341 Glioblastoma studies recruiting now, 236 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 14 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Glioblastoma with a site in China, or all of them as a file.
02

Study summary

This is an open-label dose-escalation and dose-expansion study that plans to enroll 16 to 32 adult participants with recurrent or progressive glioblastoma. Participants will be assigned to different dose groups. This study consists of two parts, namely the dose escalation stage and the dose expansion stage. The study aims to determine the safety and tolerability of the oncolytic adenovirus YSCH-01 in adult participants with recurrent or progressive glioblastoma.

03

Conditions studied

  • Recurrent Glioblastoma (WHO-Grade IV Glioma)
  • Progressive Glioblastoma
  • Recurrent Glioblastoma

Browse trials for

Keywords

  • Recurrent Glioblastoma
  • rGBM
  • Progressive Glioblastoma
  • Oncolytic adenovirus
  • YSCH-01
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who are willing to sign the form (ICF), able to understand the study, and willing to follow the protocol and complete all the study procedures;
  2. Male or female aged ≥ 18 and ≤ 75 years;
  3. Disease status: Subjects with an initial glioblastoma histopathologically confirmed in accordance with the 2021 WHO Classification of Tumors of the Central Nervous System, who have developed disease recurrence or progression following standard of care. The standard of care consists of surgical resection, chemotherapy and/or radiotherapy. For subjects with known specific molecular alterations (e.g., NTRK fusions), prior standard targeted therapy recommended by the latest local guidelines is required, except for subjects for whom the investigator judges standard of care to be inapplicable, of limited benefit, or intolerable; the rationale for intolerance shall be documented.
  4. Patients with at least one (≥10 mm in both perpendicular diameters as per RANO 2.0 criteria) within 4 weeks before YSCH-01 treatment;
  5. Subjects with a performance status (KPS) score of ≥70 and the expected survival period is ≥ 3 months;
  6. Subjects with adequate organ and hematopoietic function:

    Hematological function: (ANC) ≥1.0×10⁹/L, (HGB) ≥90 g/L, count (PLT#) ≥100×10⁹/L. No blood transfusion, granulocyte-macrophage colony-stimulating factor (GM-CSF), recombinant human erythropoietin, recombinant human thrombopoietin, platelet receptor agonists, recombinant human interleukin-11, or other supportive treatments within 14 days prior to screening; Liver function: total (TBIL) ≤2×, except for subjects with Gilbert's syndrome; (ALT) and aspartate aminotransferase (AST) ≤3×ULN (≤5×ULN in the presence of liver ); Renal function: serum creatinine (Cr) ≤1.5×ULN; Coagulation function: in the absence of anticoagulant therapy, (PT), activated partial thromboplastin time (APTT), or international normalized ratio (INR) ≤1.5×ULN

  7. Male subjects of and female subjects of must agree to use reliable methods (hormonal contraception, barrier methods, or abstinence) during the study and for at least 6 months after the last dose of YSCH-01; female subjects of childbearing potential must have a negative blood or urine pregnancy test within 7 days prior to enrollment.

Exclusion criteria

Exclusion Criteria:

  1. Subjects with a known severe allergy to any component of the drug, Ommaya reservoir, or other oncolytic virus therapies;
  2. Pregnant or breast-feeding women;
  3. Subjects with positive results for surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb), and a hepatitis B virus deoxyribonucleic acid (HBV-DNA) level higher than the lower limit of detection; subjects with a positive result for virus (HCV) antibody and a hepatitis C virus ribonucleic acid (HCV-RNA) level higher than the lower limit of detection; subjects with a positive result for (HIV) antibody;
  4. Subjects who received chemotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor drugs within 4 weeks prior to the first dose; Chinese herbal medicines or Chinese patent medicines with anti-tumor indications within 2 weeks; Subjects who received radiotherapy within 4 weeks days prior to the first dose;
  5. Subjects with known or suspected active diseases, including but not limited to Crohn's disease, rheumatoid arthritis, systemic lupus erythematosus, etc.;
  6. Subjects who require systemic (>10 mg/day prednisone or equivalent) or other medication within 14 days prior to the first dose or during the study, with the following exceptions:

    Adrenaline replacement steroids (prednisone ≤10 mg/day or equivalent); Topical, ophthalmic, intra-articular, intranasal, or inhaled corticosteroids; Prophylactic short-term (≤7 days) use of corticosteroids (e.g., allergy to contrast media) or for the treatment of non-autoimmune diseases (e.g., delayed reactions caused by contact allergens).

  7. Subjects with tumor lesions in critical anatomic areas (e.g., ventricular invasion or proximity to the brainstem and spinal cord, or the posterior fossa);
  8. Subjects with increased intracranial pressure (e.g., impending brain herniation or requirement for immediate palliative treatment) or uncontrolled seizures;
  9. Subjects with poorly controlled mental disorders, or who, in the investigator's opinion, have a medical history or mental state that may increase the risks associated with study participation or investigational drug administration, or that may interfere with the study results;
  10. Subjects with toxicity and side effects caused by previous treatment that have not recovered to Grade ≤1 (per V6.0); except for alopecia and other tolerable events judged by the investigator;
  11. Presence of cardiovascular disease or conditions including any of the following:

    There are severe cardiac rhythm or conduction abnormalities, such as ventricular arrhythmias requiring clinical intervention, II-III degree atrioventricular block, etc.; At rest, the average obtained from 3 12-lead examinations is greater than 450ms; Within 6 months before the first administration, acute coronary syndrome, congestive heart failure, stroke or other grade 3 or above cardiovascular events occurred; The (NYHA) cardiac function classification is ≥ II grade or the (LVEF) is less than 50%; Any factors that increase the risk of QTc prolongation or arrhythmia, such as heart failure, hypokalemia, congenital long QT syndrome, long QT syndrome family history or a first-degree relative having sudden death before the age of 40 that cannot be explained, or using any known drugs that can prolong the QT interval.

  12. Subjects who have participated in other interventional clinical studies within 1 month prior to study treatment;
  13. Subjects who have previously received oncolytic virus therapy ;
  14. Subjects with any for undergoing an Ommaya reservoir implantation procedure;
  15. Subjects with any contraindication to magnetic resonance imaging (MRI), including pacemakers, epicardial pacing wires, infusion pumps, surgical and/or aneurysm clips, shrapnel, metal prostheses, or implants with potential magnetic properties;
  16. Subjects with any serious or poorly controlled disease that, in the investigator's opinion, may increase the risks associated with study participation, investigational drug administration, or affect the subject's ability to receive the investigational drug, including but not limited to cardiovascular and cerebrovascular diseases, renal insufficiency, pulmonary embolism, coagulopathy, conditions requiring long-term anticoagulant therapy, active infection, and uncontrollable infection requiring long-term systemic treatment;
  17. Subjects who have alcoholism, drug use or drug abuse;
  18. Subjects with other malignant neoplasms within the past 3 years or currently, except for non-melanoma skin cancer and carcinoma in situ (e.g., cervical, bladder, and breast carcinoma in situ);
  19. Subjects who receive within 4 weeks prior to the first dose or planned during the study period;
  20. Subjects with other conditions that, in the investigator's opinion, render the subject unsuitable for enrollment..
Terms in these criteria, in plain language(30)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
32 participants (estimated)

Study arms

  • Experimental
    Dose Escalation

    Participants will receive the investigational product during the dose-escalation phase. The low-dose Dose cohort will enroll 3 participants initially. If no dose-limiting toxicities (DLTs) are observed in these 3 participants during the protocol-defined DLT observation period, enrollment at the higher dose level may proceed in accordance with the protocol-defined dose-escalation criteria. Safety and tolerability will be evaluated to determine the dose for further investigation.

    Drug: YSCH-01

  • Experimental
    Dose Expansion

    Participants will receive the trial product at the selected dose level based on the results of the dose escalation phase. The dose expansion phase will further assess the safety and tolerability of the selected dose, and evaluate its initial anti-tumor activity under the same overall disease population and the same primary inclusion criteria.

    Drug: YSCH-01

Interventions

  • DrugYSCH-01

    After being enrolled, the participants underwent tumor biopsy/ resection and then an Ommaya reservoir was implanted into the tumor. The participants would receive single-agent treatment with YSCH-01 every 3 weeks. YSCH-01 was administered within the tumor through the implanted Ommaya reservoir.

    Also known as: Recombinant L-IFN adenovirus injection

06

What researchers measure

Primary outcomes

  1. Incidence of Dose Limiting Toxicities (DLT)

    During the DLT observation period following the administration of YSCH-01, the incidence of DLTs will be evaluated. The occurrence of DLTs will be determined according to the criteria specified in the protocol

    Time frame: 21 days after the first dose and 21 days after the second dose

  2. Safety and tolerability assessed by Adverse Events (AEs)

    The incidence, severity, seriousness, and relationship to YSCH-01 of adverse events (AEs) will be assessed. Cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) will be graded according to the American Society for Transplantation and Cellular Therapy (ASTCT) 2018 consensus grading criteria. All other AEs will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 6.0. Adverse events will be characterized by type, severity grade, seriousness, relationship to the investigational product, and outcome

    Time frame: From first dose up to 28 days after last dose

Secondary outcomes

  1. Overall Survival (OS)

    The time from the first dose to death from any cause

    Time frame: From the first dose to 1 year post first dose

  2. Progression-free survival (PFS)

    To evaluate progression-free survival per Response Assessment in Neuro-Oncology (RANO) , version 2.0 criteria

    Time frame: From the first dose to the date of documented disease progression or death from any cause, whichever occurs first, assessed for up to 6 months

  3. Viral Biodistribution of YSCH-01 in Blood

    Viral DNA levels of YSCH-01 in blood will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate the biodistribution of YSCH-01 Unit of Measure: Copies/μg DNA

    Time frame: Baseline (within 2 hours before the first dose); 2, 4, 6, 24, 72, and 168 hours post first dose; predose and 2, 6, and 24 hours post the second to fifth dose; end of treatment (up to 1 year); 28 days after the last dose

  4. Viral DNA Shedding of YSCH-01 in Feces

    Viral DNA levels of YSCH-01 in feces samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment Unit of Measure: Copies/μg DNA

    Time frame: Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose

  5. Viral DNA Shedding of YSCH-01 in Urine

    Viral DNA levels of YSCH-01 in urine samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment Unit of Measure: Copies/reaction

    Time frame: Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose

  6. Viral DNA Shedding of YSCH-01 in Nasopharyngeal Fluid

    Viral DNA levels of YSCH-01 in nasopharyngeal fluid samples will be measured by quantitative real-time polymerase chain reaction (qPCR) to evaluate fecal viral DNA shedding following treatment Unit of Measure: Copies/reaction

    Time frame: Baseline (within 24 hours before the first dose); 24, 48, 72, and 168 hours post first dose; end of treatment (up to 1 year) and 28 days after the last dose

  7. Pharmacodynamic (PD): Serum IL-2 concentration

    Serum IL-2 concentrations will be measured using the MSD assay Unit of Measure: pg/mL

    Time frame: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

  8. PD: Serum IL-6 Concentration

    Serum IL-6 concentrations will be measured using the MSD assay Unit of Measure: pg/mL

    Time frame: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

  9. PD: Serum IL-8 Concentration

    Serum IL-8 concentrations will be measured using the MSD assay Unit of Measure: pg/mL

    Time frame: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

  10. PD: Serum IL-10 Concentration

    Serum IL-10 concentrations will be measured using the MSD assay Unit of Measure: pg/mL

    Time frame: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

  11. PD: Serum IL-12 concentration

    Serum IL-12 concentrations will be measured using the MSD assay Unit of Measure: pg/mL

    Time frame: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

  12. PD: Serum TNF-α concentration

    Serum TNF-α concentrations will be measured using the MSD assay Unit of Measure: pg/mL

    Time frame: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

  13. PD: Serum IFN-γ concentration

    Serum IFN-γ concentrations will be measured using the MSD assay Unit of Measure: pg/mL

    Time frame: Pre-2 hours and 6, 24, 72, 120, and 168 hours post first dose; pre-2 hours and 6, 24, 72, 120, and 168 hours post forth dose; pre-2 hours of the second, third and fifth dose; at the end of treatment (up to 1 year)

  14. Anti-drug antibody (ADA) of adenovirus

    Serum levels of anti-YSCH-01 antibodies will be measured by enzyme-linked immunosorbent assay (ELISA) before and after treatment. Antibody levels will be reported in ng/mL Unit of Measure: ng/mL

    Time frame: Pre-2 hours of each dose; at the end of treatment (up to 1 year)

Other outcomes

  1. Changes of immune cell infiltration and the tumor microenvironment in paired tumor tissue samples

    Paired tumor tissue samples collected at baseline and after treatment from participants undergoing repeat surgery will be analyzed to characterize changes in immune cell infiltration, immune cell populations, tumor immune microenvironment (TME) remodeling, and stromal composition following treatment

    Time frame: At baseline surgery and at post-treatment repeat surgery, when available, within 1 year after the first dose

  2. Cell-Free DNA (cfDNA) Levels in Cerebrospinal Fluid and Peripheral Blood

    Cell-free DNA (cfDNA) levels in cerebrospinal fluid (CSF), when available, and peripheral blood will be assessed using next-generation sequencing (NGS) or other validated molecular assays to explore their associations with treatment response

    Time frame: At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available

  3. Cytokine Profiles in Cerebrospinal Fluid

    Concentrations of IL-2, IL-6, IL-8, IL-10, IL-12, TNF-α, and IFN-γ in cerebrospinal fluid (CSF) will be measured using the MSD assay, consistent with the peripheral blood pharmacodynamic (PD) cytokine assessments. Each cytokine will be reported separately in pg/mL to explore treatment-related changes and their associations with treatment response Unit of Measure: pg/mL

    Time frame: At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available

  4. Absolute Counts of Immune Cell Populations in Cerebrospinal Fluid and Peripheral Blood

    Absolute counts of T cells, B cells, NK cells, and myeloid cells in cerebrospinal fluid (CSF) and peripheral blood will be characterized using flow cytometry. The absolute counts of each immune cell population will be reported separately in cells/mL to explore treatment-related changes and their associations with treatment response Unit of Measure: cells/mL

    Time frame: At baseline and at selected time points during treatment (up to 1 year, determined by the researcher), when samples are available

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Nov 2026; primary completion for Dec 2028, 25 months later.

Of 82 industry-sponsored phase 1 interventional studies under Glioblastoma, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's planned 25 months is below that.

Counting every sponsor, half of 321 studies reached it within 44 months; a quarter within 29 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 1, 2026
First posted
Nov 19, 2026
StartEst.
Nov 10, 2026
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2029
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07948109
Lead sponsor
Shanghai Yuansong Biotechnology Co., Ltd.
Responsible party
Sponsor
First posted
Nov 19, 2026
Start date
Nov 10, 2026 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Dec 2029 (estimated)
Last update
Nov 19, 2026

Study contacts

Yiyan Xu
Contact
xuyiyan@yuansongbio.com
+86-021-60975992

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion